OVID THERAPEUTICS INC. - COMMON STOCK

Ovid Therapeutics to Present at the 23rd Annual Needham Virtual Healthcare Conference

04 Apr 2024 08:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports Business Updates, Fourth Quarter and Full Year 2023 Financial Results

08 Mar 2024 08:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the TD Cowen 44th Annual Health Care Conference

28 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the Oppenheimer 34th Annual Healthcare Life Sciences Conference

06 Feb 2024 08:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present Five Abstracts Supporting its Epilepsy Programs at the 77th American Epilepsy Society Annual Meeting (2023)

01 Dec 2023 07:30:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports Third Quarter 2023 Financial Results and Corporate Updates

03 Nov 2023 08:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics and Ligand Pharmaceuticals Enter into a $30 Million Agreement for a 13% Interest in Soticlestat Royalties and Milestones Extending Ovid’s Cash Runway into 2026

18 Oct 2023 08:00:01 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the Jefferies Biotech CNS/Neuro Summit

10 Oct 2023 08:00:01 By Nasdaq GlobeNewswire

Ovid Therapeutics to Host Investor Event - R&D Day on Monday, October 2, 2023

26 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the 2023 Cantor Fitzgerald Global Healthcare Conference

20 Sep 2023 07:30:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Participate in Upcoming September Investor Conferences

30 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports Second Quarter 2023 Financial Results and Corporate Updates

04 Aug 2023 08:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the BTIG Virtual Biotechnology Conference 2023

01 Aug 2023 08:00:01 By Nasdaq GlobeNewswire

Ovid Therapeutics Expands Its Scientific Leadership Team & Appoints Chief Strategy Officer

28 Jun 2023 08:00:01 By Nasdaq GlobeNewswire

Ovid Therapeutics Added to Russell 3000® Index

26 Jun 2023 08:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports First Quarter 2023 Financial Results and Corporate Updates

05 May 2023 07:30:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Announces Collaboration with Graviton Bioscience, Proven Developers of Selective ROCK2 Inhibitors

01 May 2023 06:00:00 By Nasdaq GlobeNewswire

Long-term Safety & Efficacy Findings from Soticlestat Open Label Extension Study Presented by Takeda at American Academy of Neurology Annual Meeting

27 Apr 2023 14:30:14 By Nasdaq GlobeNewswire

Ovid Therapeutics to Present at the 22nd Annual Needham Virtual Healthcare Conference

10 Apr 2023 08:00:00 By Nasdaq GlobeNewswire

Ovid Therapeutics Reports Business Update, Fourth Quarter and Full Year 2022 Financial Results

13 Mar 2023 08:00:01 By Nasdaq GlobeNewswire